Intralesional injection of collagenase Clostridium histolyticum (CCH) is a minimally invasive, Food and Drug Administrationapproved, effective treatment for Peyronie's disease (PD). To assess the satisfaction of patients and their female sexual partners (FSP) following CCH therapy for PD, we conducted a retrospective review of the records of all patients treated with CCH for PD between 04/2014 and 03/2016. Collected variables included demographics, pre-and post-treatment sexual function, penile curvature, penile vascular findings, and treatment outcomes. Patients and their FSPs were subsequently contacted by telephone and queried regarding their ability to have intercourse and their satisfaction with treatment. A total of 24 couples responded to our questionnaire and constitute the subjects of this analysis. Patient and FSP satisfaction with treatment were 67% and 71%, respectively. Significant predictors of FSP satisfaction with treatment included recall of penile trauma during prior sexual intercourse, improved ability to have sexual intercourse following treatment, and absence of post-procedural glans hypoesthesia. In conclusion, CCH imparts a significant benefit on a couple's sexual health. Partner satisfaction with treatment is correlated with improved ability to have sexual intercourse and absence of patient glans hypoesthesia.
INTRODUCTION
Peyronie's disease (PD), defined as the abnormal deposition of collagen in the tunica albuginea of the penis, represents a relevant cause of sexual dysfunction. Although its prevalence is often underestimated, recent data suggest that 2-9% of the U.S. male population is afflicted (Lindsay et al., 1991; Sommer et al., 2002; Mulhall et al., 2004; Dibenedetti et al., 2011) . The condition generally presents in men in their late 50s with the onset of penile deformity, and is often accompanied by pain and/or erectile dysfunction (ED) (Taylor & Levine, 2007; Anaissie et al., 2015) . While penile deformity is the most often discussed effect, the psychosocial implications on the patient, as well as on his partner, are often overlooked.
PD can have a strong negative emotional impact on men, often leading to depression, low self-esteem, and relationship difficulties. Up to 77% of surveyed men indicate at least some degree of a negative psychological effect from their PD (Mulhall et al., 2004) . In one study, up to 48% of men with PD were also diagnosed with clinically significant depression (Nelson et al., 2008) . A similar report documented an 81% prevalence of emotional problems owing to PD, typically because of loss of penile length and the inability to have satisfactory intercourse (Smith et al., 2008) . Furthermore, up to 54% of studied patients reported relationship problems (Nelson & Mulhall, 2013) , demonstrating that the burden of PD is shared by both patients and their partners. Couples struggle to form an alliance to cope with PD, but men often give up fighting, leaving partners without hope. PD deeply affects the role a female partner plays in the relationship and her life alongside a man with PD (Nelson & Mulhall, 2013) .
Various medical therapies have been proposed for the treatment of PD, but none have proven as effective as collagenase clostridium histolyticum (CCH), the only injectable agent the Food and Drug Administration has approved to treat PD. Clinical trials with CCH have documented both safety and efficacy. Data from the IMPRESS (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials demonstrated that 50-60% of patients show a clinically significant >20% improvement in curvature, with a mean percent reduction in penile curvature from baseline between 30 and 40% (Jordan, 2008; Gelbard et al., 2012 Gelbard et al., , 2013 Anaissie et al., 2015; Levine et al., 2015) . The IMPRESS trials also revealed an improvement in patientreported symptoms from the Peyronie's disease questionnaire (PDQ) (Gelbard et al., 2013) . The majority of adverse events from CCH treatment include penile bruising, pain, and edema, and are mild to moderate in severity and usually resolve without intervention.
Although the positive effects that CCH can have on a patient's penile deformity and overall satisfaction have been well reported, studies investigating the impact of the man's PD on the female sexual partner (FSP) remains understudied. We sought to review our clinical database to assess patient and partner satisfaction and their predictors following CCH therapy.
METHODS

Patient population
Retrospective data were collected from 77 PD patients who underwent treatment with CCH between April 2014 and March 2016. Collected data included patient demographics, pre-and post-treatment penile curvature measurements, penile vascular findings, sexual function, and other treatment outcomes such as complications or the need for secondary procedures.
Intralesional injections of collagenase Clostridium histolyticum
Patients were qualified for CCH therapy if they had PD with a palpable penile plaque and a non-ventral curvature deformity of >30 degrees on initial penile duplex Doppler ultrasound (PDDU) measurement. Patients were included at the time of PD plaque identification, without prolonged observation for plaque stabilization before treatment. At the beginning of each cycle, an erection was induced by intercavernosal injection of alprostadil (6-20 lg) followed by marking the area of maximal curvature for injection. Repeat dosing was performed as needed to attain 
Patient questionnaire
All 77 patients and their partners were contacted by telephone and asked to complete a patient satisfaction questionnaire regarding their CCH treatment. In total, 53 patients either could not be reached by telephone, were unwilling to respond to the questionnaire, or their FSP was not amenable to answer questions, and were subsequently excluded from the study. A total of 24 couples completed the questionnaire and represent the study cohort. Patients were queried about their ability to have sexual intercourse, presence of glans hypoesthesia, whether or not they would repeat the same treatment, and overall satisfaction with treatment. Their FSPs were then queried about the presence of pain with sexual intercourse and their overall satisfaction with treatment, through binary 'yes' or 'no' questions.
Statistical analysis
Statistical analyses were performed using the SAS statistical software package version 9.1 (SAS Institute, Inc., Cary, NC, USA). A descriptive analysis of general and clinical characteristics was performed using frequency distributions. Continuous data are presented as means AE standard deviation. Two-tailed Student's t-test was used for comparisons between groups for continuous variables and chi-square tests for categorical variables. P < 0.05 was considered statistically significant.
RESULTS
Patient and treatment characteristics
For the 24 patients included in the study, mean age was 55.7 (SD 6.0) years. Median duration of PD was 24 months (range < 1 month to 120 months). Mean pre-treatment curvature was 56.5 degrees (SD 18.5) with 13 patients (54%) having pre-treatment curvature between 30 and 60 degrees, while the curvature was >60 degrees in the remaining 11 patients (46%). The mean number of cycles was 3.5 (SD 0.8), with one (4%), two (8%), six (25%), and 15 (63%) patients completing one, two, three, and four cycles, respectively. The mean post-treatment curvature, regardless of number of cycles, was 37.9 degrees (SD 18.2). The overall mean reduction in curvature with CCH therapy, regardless of number of cycles or patient satisfaction, was 16 degrees (SD 10.7) ( Table 1) .
Patient satisfaction
Sixteen of 24 patients (67%) reported overall satisfaction with treatment. There were no significant differences between the characteristics of satisfied and unsatisfied patients (Table 2) .
Female partner satisfaction
Seventeen of 24 FSP (71%) were satisfied with treatment. The characteristics of FSPs with regard to overall treatment satisfaction are shown in Table 3 . Factors associated with FSP satisfaction included a positive patient history of penile trauma, ability to have intercourse following treatment, and absence of postprocedural glans hypoesthesia (Fig. 1) .
DISCUSSION
To the best of our knowledge, this is the first published study assessing the potential predictors of patient and FSP satisfaction following treatment of PD with CCH. FSP satisfaction is associated with a positive patient history of penile trauma, ability to have intercourse following treatment, and absence of post-procedural glans hypoesthesia.
Current research describing the effects of CCH therapy on FSP is lacking. In a phase 3, open label study with 189 men treated 
Not satisfied (n = 7) Satisfied (n = 17) 276 Andrology, 2017, 5, 274-277 with CCH, FSPs reported improvement in their partner's PD symptoms and in female bother by their partner's PD (Goldstein et al., 2015) . In this study, FSPs completed the female sexual function index (FSFI) and the Peyronie's disease questionnaire for FSPs (PDQ-FSP), which is adapted from the men's PDQ. Following CCH treatment, FSPs reported mean score reductions of 4.8 and 2.0 on the PDQ-FSP in both their male partner's PD symptoms and female bother by their partner's PD. Improvement was also observed on the FSFI scales of desire, arousal, lubrication, orgasm, satisfaction, and pain, as well as the full scale total scores. Overall, the proportion of FSPs who reported sexual dysfunction decreased from 75% at baseline to 33.3% after partner treatment. Thoroughly understanding the relationship between CCH therapy and FSP satisfaction is an important component of managing PD-associated psychological stressors. A history of traumatic injury to the penis is a common finding in PD, and is thought to be a precipitating factor (Jarow & Lowe, 1997; Nehra et al., 2015) . One theory for improved FSP satisfaction in the setting of traumatic penile injury is that a history of trauma, which is usually derived from vigorous sexual intercourse (Jarow & Lowe, 1997) , may lead to feelings of responsibility and guilt in the FSP. After CCH therapy, improved sexual function may alleviate these negative feelings and lead to an increased satisfaction with treatment.
P-value
A second association between FSP satisfaction and treatment identified in this study was the ability to have sexual intercourse after CCH treatment. This finding is expected, because one of the biggest psychological stressors for patients suffering from PD is the decline in erectile function. Upon restoration of their lost ability, patients are more likely to engage in sexual intercourse, thus leading to improved FSP satisfaction with treatment.
Lastly, the absence of post-procedural glans hypoesthesia after CCH treatment predicted FSP satisfaction with treatment which may be a reflection of a pleasurable male partner experience (Fallis et al., 2016) . With intact sexual sensation, patients may engage in more passionate, healthy sexual intercourse when compared to their previously hindered physical and emotional state. This improved sexual experience is likely also enjoyed by the patient's FSP, leading to her satisfaction with CCH therapy.
This study has limitations, including its retrospective design, relatively small sample size, and single-center experience. A further study limitation is the heterogeneity in the number of cycles received, with only 63% of patients completing all four cycles of treatment, because of discontinued or ongoing treatment. Another limitation is patient participation. By only collecting data from couples who responded to the questionnaire, a selection bias may have been introduced because of decreased participation from patients who were not satisfied with treatment. Lastly, the patient and partner questionnaires used in this study have not been validated. The PDQ is the only currently available validated questionnaire for PD, but it does not, however, take into account partner satisfaction with treatment. Multicenter, randomized controlled trials with larger sample sizes utilizing validated questionnaires are needed to further analyze the predictive value of the associations reported in this study, and further describe the effects of treatment on FSP.
CONCLUSIONS
CCH imparts a significant benefit on a couple's sexual health. FSP satisfaction with treatment is correlated with recall of prior penile trauma, improved ability to have sexual intercourse, and absence of post-procedural glans hypoesthesia. These preliminary findings may help clinicians understand the implications of treatment on patient's FSP.
